- Home
- NOMA vs RNAZ Comparison
NOMA vs RNAZ Comparison
Compare NOMA & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NOMA | RNAZ |
|---|---|---|
| Founded | 2023 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.2M | 27.9M |
| IPO Year | 2025 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NOMA | RNAZ |
|---|---|---|
| Price | $1.57 | $1.70 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 16.9K | ★ 48.9K |
| Earning Date | 11-18-2026 | 08-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,376.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.31 | $1.52 |
| 52 Week High | $10.00 | $13.92 |
Technical Indicators
Market Signals| Indicator | NOMA | RNAZ |
|---|---|---|
| Relative Strength Index (RSI) | 43.25 | 46.15 |
| Support Level | $1.40 | $1.55 |
| Resistance Level | $2.09 | $1.93 |
| Average True Range (ATR) | 0.23 | 0.17 |
| MACD | 0.02 | 0.07 |
| Stochastic Oscillator | 6.75 | 65.85 |
Price Performance
Historical ComparisonAbout NOMA NOMADAR Corp.
Nomadar Corp operates at the intersection of sports and technology, focusing on high-performance training programs and cultural exchange. The company aims to connect athletes, coaches, and fans through inventive technological solutions, enhancing sports development beyond physical borders. It offers services like the High Performance Training (HPT) program and promotes the legacy of iconic athletes. The Company generates revenue through its High Performance Training Program and events management at the JP Financial Stadium.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.